Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc.
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 35.14 percent increase over losses of $(0.37) per share